A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer.
Latest Information Update: 21 Apr 2023
Price :
$35 *
At a glance
- Drugs Ibandronic acid (Primary) ; Zoledronic acid (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 12 Nov 2007 New trial record.
- 31 May 2006 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.